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It is well established that CD4 acts as the principal receptor for the binding of
HIV to T cells (1-4) . However, as the number of identified cellular targets forHIV
infection has expanded, it has been hypothesized that other receptors forHIVmay
exist (5-7) . There is recent evidence, for example, that some muscle or glioma cell
lines that lack detectable surface CD4 may be infected by HIV (5). Moreover, it
has been observed that infection ofhuman lymphocytes or the monocytoid cell line
U937 by HIV can be enhanced by low titers ofanti-HIV antibodies, and it has been
hypothesized that Fc receptors or complement receptors may act as an entry site
for HIV under these conditions (6-8).
Human peripheral blood monocyte/macrophages (M/M)t can be easily infected
by certain strains of HIV, and there is increasing evidence that infection of such
cells plays a crucial role in the pathogenesis and progression ofAIDS and related
disorders (9, 10) . M/M are phagocytic cells, and it seemed possible that this could
providearoutefor viralentry. In addition,M/Mbear Fc and complement receptors
and, in the case ofcertain otherviruses (e.g ., flaviviruses), are prime targets foren-
hancement ofinfection by antiviral antibodies (11-13). It therefore seemed conceiv-
able that a CD4-independent pathway for infection may exist for M/M, either in
the presence or absenceoflow titers of anti-HIV antibodies . This question is poten-
tially importantfrom atherapeutic viewpoint as strategies to inhibitHIVCD4binding
are actively being investigated as therapies forHIV infection (14-19) . The present
set of experiments were designed to study whether infection ofM/M could be en-
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hanced by low titers of anti-HIV antibodies, and in addition, whether a second entry
mechanism for HIV infection of M/M might be identified, particularly in the pres-
ence of such antibodies.
Materials and Methods
Cells.
￿
Monocyte-enriched PBMC were obtained from healthy, HIV-seronegative donors
using a cell separator (Fenwall C3000; Travenol Inc., Deerfield, IL). Fresh M/M were subse-
quently purified from this population by elutriation as described by Gerrard et al. (20). In
certain experiments, the fresh elutriated M/M were cultivated for 5 d in the presence or ab-
sence of 100 chronic myelogenous leukemia (CML) U/ml ofhumanrecombinant granulocyte-
macrophage CSF (GM-CSF) (Sandoz Research Institute, East Hanover, NJ) as described
(21). Also, in certain experiments, mature adherent M/M populations (called 5-d adherent
M/M) were obtained by incubating 106 PBMC/well in 48-well plates (Costar, Cambridge,
MA) for 5 d, followed by extensive washing to remove nonadherent cells (22). Using this
method, the yield after removal of the nonadherent cells was ti 105 M/M per well. The via-
bility of cells obtained with each of these methods was consistently >95%. M/M obtained
with each ofthese methods were <1% E-rosette positive and >95% nonspecific esterase posi-
tive (Technicon Instruments, Tarrytown, NY), and >95% morphologically resembled mono-
cytes when examined after Giemsa staining. Other characteristics of these cells have been
previously described (21, 22). In certain experiments, U937, a CD4' monocytoid cell line,
or ATH8, an HTLV1-infected human T cell line (21, 22) (gift of Dr. H. Mitsuya, National
Cancer Institute, Bethesda, MD), were used.
The expression of surface antigens on the cells was assessed by flow cytometry using the
following fluorescein-conjugated mAbs: CD4, Leu-3a (Becton Dickinson & Co., Mountain
View, CA); Cdllb, OKM1 (Ortho Diagnostic Systems Inc., Westwood, MA); CD36, OKM5
(Ortho Diagnostic Systems Inc.); HLA-DR, OKla (Ortho Diagnostic Systems Inc.). Paired
isotype-specific control antibodies were run with each sample. Dead cells were excluded from
analysis using propidium iodide, and the percentage of antigen-positive cells was calculated
by straight channel integration, with the integration channel set so that <1% of the isotype
control cellsappeared positive. The density ofCD4 on the surface of the cells was compared
by staining cells with fluorescein-labeled Leu-3a mAb (Becton Dickinson & Co.), followed
by analysis on a profile flow cytometer (Coulter Electronics Inc., Hialeah, FL). Fluorescence
was then compared with appropriate fluorescein-labeled isotype controls (IgGI-FITC ; Becton
Dickinson & Co.) using logarithmic-to-linear conversion tables supplied by Coulter Electronics
Inc. The mean channel of positive fluorescence was then calculated by the following formula:
mean channel antibody peak minus mean channel isotype control peak.
Virus.
￿
A monocytotropic strain of HIV1, HTLVIIIR~-L (gift of Drs. S. Gartner, R. C.
Gallo, and M. Popovic, National Cancer Institute) (9), and a lymphocytotropic strain of HIV-1,
HTLVIIIB (Electro-Nucleonics Laboratory, Inc., Silver Spring, MD), were used as previ-
ously described (22). These will be referred to as HIV1Rd_L and HTLVIIIB, respectively.
Supernatants from infected cultures of fresh M/M were used as the source of HIVRa-L; these
were filtered and stored in liquid nitrogen before use. Titration to determine infectivity was
performed in a primary M/M system; the minimum infectious dose (MID) was defined as
the minimum amount of virus that induced viral replication in at least two of four M/M
cultures. Pelleted supernates of infected H9 cells that were concentrated by centrifugation
were used as the source of HTLVIIIB. The MID of this strain was assessed in the AHT8
cell line (23, 24).
Anti-HIVAntibodies.
￿
Preparations ofhuman antibodies to HIV (called HIVAbl and HIV-
Ab2) were the gifts of Dr. Larry Cummins, Abbott Laboratories, Irving, TX. These anti-
bodies were prepared from the plasma ofasymptomatic, HIVinfected individuals who lacked
detectable serum HIV p24 antigen, HIVAbl was prepared from donors who had high titers
of antibody to p24 and gp120 but low titers ofantibody to gp4l. HIVAb2 was prepared from
a donor who had high titers ofantibody to gp120 and gp4l, but no detectable anti-p24 anti-
body. Plasma from these donors was inactivated by treatment with 1 170 tri-N-butyl-phosphate
and 1% Tween 80 for 4 h at 30°C, and fractionated by the Cohn-Oncley cold ethanol proce-PERNO ET AL.
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dure (25, 26). Additional purification was obtained using QAE Sephadex gel (27). The final
preparation contained >95% monomeric IgG as determined by HPLC. These preparations
were then diluted at 50 mg/ml in saline, sterile filtered, and stored at 4'C until used. A con-
trol preparation of human IgG, obtained from HIVseronegative donors, was purified in the
same manner.
Preliminary experiments showed that HIVAbl, but not HIVAb2, interfered with the RIA
used to measure HIV p24 antigen (Dupont Co., Wilmington, DE). However, even at the
highest concentration used (5,000 Ftg/ml), the washing procedure performed 48 h afterviral
challenge (see below) reduced the concentration of antibody by -10-s, so that it no longer
had any detectable effect on the assay. Neither antibody preparation interferedwith the ELISA
used to measure HIV p24 antigen (Dupont Co.), even at the highest concentrations used.
Anti-HIVAgents and Controls.
￿
Recombinant soluble CD4 (sCD4) containing the four ex-
tracellular domains was provided by Dr. Dan Capon of Genentech, Inc. (So. San Francisco,
CA) (14). OKT4A, an IgG2a murine mAb against CD4 (Ortho Diagnostic Systems, Inc.),
OKT4C (Ortho Diagnostic Systems Inc.), another IgG2a anti-CD4 murine mAb that binds
to a different determinant, and D3-2H2-9-21 antidengue antibody (American Type Culture
Collection, Rockville, MD), an IgG2a murine mAb used as an isotype control, were diluted
in PBS, extensively dialyzed against PBS, and passed through a 0.4-Am filter before use. The
final protein concentration in these preparations was evaluated by spectrophotometric mea-
surement. All reagents were stored at 4'C until used.
Infection andCulture ofMIMPopulations.
￿
105 M/M prepared by the various techniques de-
scribed above (fresh elutriated cells, elutriated cells cultured 5 d with or without GM-CSF,
or 5-d adherent M/M) were suspended in RPMI 1640 medium (Gibco Laboratories, Grand
Island, NY) supplemented with 20% heat-inactivated low-endotoxin FCS (HyClone Labora-
tories, Logan, UT), 2 MM L-glutamine, 50 U/ml penicillin, and 50 pg/ml streptomycin (Gibco
Laboratories) (complete medium). The cells were exposed to various concentrations ofsCD4,
OKT4A, OKT4C, or D3-2H2-9-21 for 30 min to 2 h at 37°C, challenged with 100-500
MID/well of HIV-1R,-L, and incubated at 37'C in a humidified atmosphere supplemented
with 5% C02. In some experiments, the sCD4 or antibodies were added to the cultures 1
or 6 d after the viral challenge. 2 d after viral exposure, the M/M were extensively washed
to remove excess virus and then cultured under the same conditions and drug concentrations
as before. The supernatant was partially replaced with fresh complete medium every 5 d.
Viral production into the supernatant was evaluated every 4-5 d starting from day 6 by RIA
or ELISA for HIV p24 antigen (Dupont Co.). In some experiments, inhibition of syncytia
formation by these agents was evaluated by visual inspection; this was only done in cultures
ofmature or GM-CSFexposed M/M, as fresh M/M usually do not form syncytia in our hands.
Evaluation ofthe Effects ofAnti-HIVAntibody.
￿
To evaluate the enhancement of HIV infec-
tion by low concentrations of anti-HIV antibody, 3 MID/well of HIV-1R,_,, was mixed with
serial 10-fold dilutions of HIVAbl or HIVAb2 in 200 p,l ofcomplete medium and incubated
at 4°C for 2 h. The virus-antibody mixtures were then added to fresh or 5-d adherent M/M
that were previously incubated for 30 min at 4°C with sCD4, OKT4A, D3-2H2-9-21, or
control medium in 48-well plates. The cells were cultured for 2 d at 37°C in a humidified
atmosphere supplemented with 5% C02 as described above. The M/M were then washed
extensively to remove excess virus, sCD4, or antibodies, resuspended in 1 ml of complete
medium (without either anti-HIV antibody or other agents), and continued in culture. They
were fed every 5 d, as above, and viral production into the supernatants was periodically
assessed as described above.
Toxicity Assessments.
￿
The toxic effects of antibodies or sCD4 were assessed by the trypan
blue dye exclusion method, by evaluation of phagocytosis of 0.8-Am latex beads, and by mea-
sure of ['H]thymidine incorporation in the U937 cell line. For the latter, 2 x 104 U937
cells/well were suspended in 0.2 ml of complete medium in wells of a 96-well plate (Costar)
and then cultured for 5 d in the presence or absence of different concentrations of sCD4,
OKT4A, D3-2H2-9-21 antibody, HIVAbl, or HIVAb2 . Cells were then pulsed for 6 h with
1 p,Cu of [3H]thymidine, harvested, and counted in a liquid scintillation spectrometer
(Beckman Instruments, Inc., Palo Alto, CA).
Statistics.
￿
The statistical significance ofthe effects of OKT4A and sCD4 was assessed with
the two-sided Wilcoxon signed rank test for paired values.1046
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Results
The expression ofsurface antigens on the various M/M populations is shown in
Table I. Most ofthe M/M expressed CD11b and HLA-DR. Fresh elutriated M/M
also expressed CD36; however, consistent with previous results (22), we found that
expression of this antigen declined somewhat in mature, cultured M/M. The ex-
pression ofCD4 was quitevariable in the M/M populations, with the meanexpres-
sion ranging between 39% in M/M cultured with GM-CSF and 56% on elutriated
M/M cultured without GM-CSF Ineach instance, however, the percentage ofM/M
expressing CD4 was less than either Th cell clones (such as ATH8) or the U937
monocytoid cell line (Table I, and results not shown). In addition, those M/M that
expressed CD4 generally had a low density of antigen as compared with ATH8 T
cells (fivefold less) or U937 cells (twofold less) (Fig. 1). These results indicated that
while some M/M expressed CD4, overall, the expression of this antigen was less
in this population than in prototype CD4+ T cells.
With this background, we asked whetherOKT4Aor sCD4, two agents that block
thebindingofHIVenv gp120 toCD4, inhibited HIV-1 infection ofthevarious M/M
populations. As seen in Fig. 2 A, fresh M/M exposed to 100-500 MID/well of
HIVB,,-L produced substantial amounts ofHIV p24 antigen starting after 2 wk and
continuing atleast up today35. However, HIV replicationwas inhibitedthroughout
this period ofobservation bythe addition of1 ,ug/ml ofOKT4A or 5 hg/ml ofsCD4
(Fig. 2 A); these concentrations are equal to or less than the concentrations ofthese
agents required to inhibit T cells. Similar results were observed with 5-d adherent
M/M and with elutriated M/M precultured for5 d with or without GM-CSF (Fig.
2 B, and results not shown). It is worth stressing that while GM-CSFstimulated
M/M had a relatively low expression of surface CD4, and in the absence ofinhibi-
TABLE I
Expression of Surface Antigens on Various Monocyte Populations
Used in these Studies
Expression ofvarious surface antigens of the various M/M populations and of
the U939 monocytoid cell line, as assessed by flow cytometry using the follow-
ing fluorescein-conjugated mAbs: CD4, Leu-3a; CDllb, OKM1; CD36, OKM5;
HLA-DR, OKla. Data reported represent the range and arithmetic mean ( t
SD) of cells prepared from four to eight different donors.
Monocyte population CD4
Percent positive cells using:
CDllb CD36 HLA-DR
Fresh elutriated M/M 13-80 95-99 93-98 90-97
(45 t 28) (97 ± 1) (96 t 3) (94 f 5)
Elutriated M/M 27-83 74-98 39-99 87-99
cultured 5 d (56 t 19) (84 t 11) (64 t 25) (91 .5 t 1)
Elutriated M/M cultured 11-62 87-96 3-67 68-93
5 d with GM-CSF (39 t 26) (92 t 5) (39 f 32) (81 t 18)
5-d adherent M/M 33-49 68-92 12-51 77-96
(40 t 8) (77 t 13) (29 t 20) (87 t 13)
U937 97-99 72-75 74-75 1-5
(98 t 1) (74 t 3) (74.5 t 1) (3 t 2.8)W m i
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FIGURE 1.
￿
Density of CD4 on the cell surface of ATH8 T cells, and fresh M/M. Shown here
is atypical experiment in which the above cells were stained with fluorescein isothiocyanate-la-
beled Leu-3a. Thepercentages of cells expressing CD4 in this experiment were: ATH8 T cells,
96%; U937 cells, 99%; fresh M/M, 70%. The mean positive channels (log scale) for ATH8 T
cells, U937 cells,,and fresh M/M were 103.3, 40.1, and 20.6, respectively.
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tors produced substantially more HIV p24 antigen than the other populations (21),
the level of inhibition on this population induced by OKT4A or sCD4 was com-
parable with that of the other M/M populations.
In contrast to the above results, HIV infection ofthe M/M was not inhibited by
comparable concentrations ofOKT4C, a murine mAb that binds to a different do-
main onCD4 than does OKT4A, andthatdoes not either inhibit gp120-CD binding
orblock HIV infection ofT cells (Fig. 2 B). Also, the IgG2a control mAb, D3-2H2-
9-21, had no inhibitory activity. Thus, agents that inhibit CD4-gp120 binding, but
not control antibodies, consistentlyblocked productive HIVinfection in thevarious
M/M populations.
We next asked whether these agents might be effective if added to the cultures
after the time of initial viral challenge. As seen in Table II, partial inhibition was
still observed when OKT4A or sCD4 were added 24 h after the exposure offresh
M/M to HIVBa-1,. This may be the result ofthese agents blockingsecondary spread
ofHIV. Alternatively, thepartialactivity ofOKT4Aadded at 24h mayhave resulted
from an effect on a post-binding step ofviral replication (e.g., fusion or entry). In
contrast, ifeither OKT4A or sCD4 was added at day 6 and the supernatants har-
vested atday 10, no inhibitory effect was observed(Table II). As expected, no inhibi-
tory effect was observed ifthe IgG2a control antibody D3-2H2-9-21 was added ei-
ther at 24 h or at day 6 (Table II). Taken together, these results suggest that in the
M/M populations studied, none ofthe substances tested act at late stages of HIV
replication (e.g., viral budding). In addition, they provide evidence that neither sub-
stance was toxic for M/M per se.
More direct evidence ofalack oftoxicity ofthese substances was provided by the
TABLE II
Effect of the Time ofAddition of sCD4 and OKT4A on Inhibition
of Infection of MIM Populations by HIVBa-L
300 MID/well of HIVBa-L was added to fresh adherent M/M at day 0. sCD4,
OKT4A, or antidengue control IgG2a murine rnAb (D3-2H2-9-21) were added
either .5 h before infection (day 0), at 24 h (day 1), or at day 6, as noted. The
cultures were washed and fed on days 1 and 6, and the sCD4 or antibodies were
replenished (if previously added) at that time. On day 10, the supernatants were
harvested and assayed for HIV-p24 antigen by RIA. Neither sCD4 nor the an-
tibodies at the concentrations used interfered with the RIA for HIV-p24 Ag.
Inhibitor Day added HIV-p24 Ag at Day 10
pglml
None 3,676
sCD4 (20 wg/ml) 0 <312
1 320
6 3,570
OKT4A (2 lug/ml) 0 <312
1 1,395
6 4,705
D3-2H2-9-21 (2 hg/ml) 0 4,320
1 5,350
6 4,360fact that neither caused cell death, as evidenced by trypan blue exclusion, and that
neitheraffectedthe phagocytosis oflatex beads upto thehighest concentrations tested
(10 lug/ml OKT4A or D3-2112-9-21 and 50 ug/ml sCD4) (results not shown). To
further assess the possible toxicity ofthese agents, we examined their effects on the
proliferation ofthe U937 monocytoid cellline and found no toxic effects at the con-
centrationstested (up to 50 jAg/ml sCD4, 10 jAg/ml OKT4A, 5,000 jAg/ml HIVAbl,
or 500 jAg/ml HIVAbl plus 10 ELg/ml OKT4A; results not shown).
We next asked whether infection of the M/M populations could be enhanced by
anti-HIV antibodies and, if so, whether this might occur by a C134-independent
pathway. To assess this, we used purified IgG anti-HIV preparations as described
above. In preliminary experiments, we found that HIVAbl had neutralizing ac-
tivity against HIV infection ofATH8 cells even at a high multiplicity ofinfection
of virus (1,000 MID/well): 50% inhibition of the cytopathic effect of HTLVIIIB
was achieved with 500 Fig/ml HIVAbl, while >95% inhibition was achieved with
5,000 /~g/ml HIVAbl. This preparation did not cause appreciable toxicity at those
concentrations. Incontrast, HIVAb2 had no discernable anti-HIV activity at equiva-
lent concentrations in thisTcell system. Also, acontrol preparation ofIgGprepared
from HIVseronegative donors had no activity at up to 5,000 ttg/ml.
HIVAbl, likewise, had substantial anti-HIV activity in M/M exposed to HIVsa_I,
(3 MID/well) (Figs. 3 and 4). Interestingly, HIVAb2 also had activity against
HIVB.-L in M/M, in spite ofits not being active against HTLVIIIB in ATH8 cells
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FIGURE 3.
￿
Enhancement ofHIV rep-
lication in mature (5-d adherent)M/M
by HIVAbl and HIVAb2. 3 MID/
well of HIVE:,-L was mixedwith serial
10-folddilutions of HIVAbl or HIV
Ab2, incubatedat 4°Cfor2 h, andthen
added to the M/M. Aftera 2-d incu-
bation, the M/M were washed exten-
sively in orderto remove free virusand
antibodies, andsubsequently cultured
in 1 ml of complete medium without
antibodies.Open symbolsdenote neu-
tralizing concentrations of HIVAbl,
while closed symbols denote concen-
trations with either no effect or en-
hancing activity. Represented here is
a typical experiment; three other ex-
perimentsusingfreshor 5-dadherent
M/M yielded similar results, whilein
one experiment no enhancement was
seen. In no case was enhancement ob-
served with comparable concentrations
of a normal control IgG antibody
purified in the same way.1050
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FIGURE 4.
￿
Enhancement ofHIVreplication in mature
(5-d adherent)M/M by different concentrations ofHIV
Abl andHIVAb2, andits inhibition by OKT4A. M/M
were preincubated with OKT4Abefore challengewith
a mixture of HIV and anti-HIV antibody. After a 2-d
culture, M/Mwere extensively washed and were culti-
vated in 1 ml of complete medium; neither HIV
antibodies norOKT4Awere addedafterwashing. Closed
symbols represent M/M exposed to HIV in the pres-
ence of 1 wg/ml of OKT4A. Open symbols represent
M/M exposed to HIV in the absence of OKT4A. (0,
40) HIVAbl; (p, 0) HIVAb2. Represented here is
a typical experiment ofsix usingeither freshor 5-d ad-
herent M/M. Inhibition of syncytia formation by
OKT4A was also observed in these cultures.
(Fig. 4). This differential activity may have been due in partto thelowermultiplicity
of infection used in the M/M cultures. However, 50 /Ag/ml of either HIVAbl or
HIVAb2 inhibited infection ofbothfresh and mature M/Mexposed to 300MID/well
of HIVBa-L (data not shown), suggesting that these antibodies were indeed more
potent inhibitors of HIV in the M/M than in T cells. It is possible that differences
between the virus preparations used, or alternatively intrinsic differences between
the target cells, may have contributed to these effects.
It has previously been reported that low levels ofanti-HIV antibodies can para-
doxically enhance HIV infection oflymphocytes or the U937 monocytoid cell line
(6, 8, 28). We next sought to determine whetherHIVAbl orHIVAb2hadenhancing
activity and, if so, whether this was inhibited by OKT4A or sCD4. In cultures of
M/M using a high multiplicity ofinfection (300 MID/well of HIVBa-L), we found
no or inconsistent evidence ofenhancement (data not shown) . However, when we
used a lower multiplicity ofinfection(3-10 MID/well), an increase in HIVinfection
(enhancement) was observed in mature (5-d adherent) M/M with extremely low
concentrations of HIVAbl or HIVAb2 (5 x 10-2 to 5 x 10-4 Fig/ml) in four of
five experiments (Fig. 3). The degree of enhancement averaged four- to fivefold.
Also, in five additional experiments using 3 MID/well ofHIVBa-L, productive in-
fection offresh or 5-d adherent M/M was attained only in the presence of5 x 10-4
to 5 x 10-6 p.g/ml of HIVAbl or HIVAb2 (Fig. 5). In no case was enhancement
observed using a control IgGpreparation. The addition ofcomplement had no con-
sistent effect on enhancement in this system . In this regard, it should be remem-
bered that these antibody preparations contained >95°Jo monomeric IgG, and these
results do not exclude the possibility that complement may affect the results seen
with other antibody preparations. Enhancement ofinfection in M/M was not re-
stricted to HIVB.-L; in the one experiment where this was examined, 100 MID/well
ofHTLVIIIB (a lymphocytotropic strain) failed to infect fresh M/M in theabsence
of antibody, while productive infection was observed in the presence of 5 x 10-3PERNO ET AL .
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FIGURE 5 . Enhancement of
HIV replication in fresh M/M
exposed to 3MIDofHIV-1 with
or without HIVAbl in the pres-
ence or absence ofOKT4A or
sCD4 . OKT4A or sCD4 were
added to the cultures before
viral exposure andnot replaced
after extensive washing at day
2 . (Open bars) M/M + HIV ;
(filled bars) M/M + HIV +
HIVAbl ; (hatched bars)M/M +
HIV + HIVAbl + OKT4A
(1 Aglml) ; (stippledbars) M/M +
HIV + HIVAbl + sCD4 (5
kg/ml) . Shown here is one rep-
resentative experiment ofthree
in whichwe detected consistent
infection only whenM/M were
exposed toHIV in the presence
ofHIVAbl . No detectable in-
fection ofM/Mwas obtained in
two additional experiments (to-
tal five) performed using a low
MID of HIVR-t, .
hg/ml ofHIVAbl (data not shown) . Overall, with HIVsa_t_, there was variation in
theoptimal concentration of antibodies yielding enhancement in M/M populations
from various donors (range from 5 x 10-2 to 5 x 10-6 Fog/ml) . In addition, there
wasvariation in thedegree ofenhancement . However, although the effect was some-
times moderate and was observed only with a low viral inoculum and very low con-
centrations ofantibody, this wasareproducible phenomenonunder theseexperimental
conditions .
It has been hypothesized that antibody-mediated enhancement ofHIV infection
might involve viral binding and entryvia a CD4-independentmechanism (6-8, 28) .
To explore this possibility, we studied the effect of OKT4A and sCD4 onM/M in-
fection that was enhanced by anti-HIV antibodies . The results obtained in repre-
sentativeexperiments are shown in Figs . 4 and 5. Infection ofeither fresh or mature
M/M under conditions ofenhancement (and with a low MID/well ofHIVBa-L) was
consistently inhibited by >95% by 1-5 hg/ml of OKT4A or by 5 hg/ml of sCD4 .
Inhibition was observed even when these agents were removed from the cultures
2 d after viral exposure . Inhibition was seen both in experiments where there was
infection of the M/M in the absence of anti-HIV antibody (Fig. 4) and in experi-
ments where infection was only observed in thepresence ofanti-HIV antibody (Fig .
5) . Overall, inhibition by OKT4A and bysCD4 was seen in each of six experiments
where this was examined (p < 0.05) .
We also examined the activity of OKT4A in U937 cells exposed to HTLVIIIB
in the presence of low concentrations of anti-HIV antibodies . We found that viral
production was increased in the presence of 5 x 10' to 5 x 10-4 Ag/ml of HIV
Abl orHIVAb2 . At the same time, complete inhibition ofinfection ofthesemonocy-
toid cells was observed with 5 Ag/ml ofOKT4A, even under conditions of enhance-
ment (data not shown) . It is worth stressing that our system used a measurement1052
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ofHIV p24 antigen produced directly by the M/M or the U937 cells and did not
involve a second "indicatorcell" population. Also, M/M were subjected to extensive
washing to remove excess virus after viral challenge, as previously described (22),
and additional controls were established in each experiment toverify this point. Fi-
nally, neither the anti-HIV antibodies, nor the OKT4A or sCD4 at the concentra-
tions in the supernatants, had any appreciable effect on the assays used to measure
HIV p24 antigen.
One concern in these experiments was that by binding to HIV, sCD4 might
somehow interfere with subsequent viral fusion or entry, and that inhibition might
occur even if HIV entered by a CD4-independent pathway. However, this concern
would not apply for OKT4A. On the other hand, the effect of OKT4A could con-
ceivably have resulted from competitive inhibition ofOKT4A with the anti-HIV
antibodies for binding to the Fc receptor on the M/M. However, 5 ug/ml of D3-
2H2-9-21 (an irrelevant murine mAb ofthe same isotype as OKT4A) failed to in-
hibit HIV infection of5-d adherent M/M that was enhanced by low concentrations
of HIVAb1 (data not shown). Thus, the overall evidence suggests that binding of
gp120 to CD4 is an essential step in the infection of these M/M populations by
HIVH.-t., even in the presence of enhancing antibodies.
Discussion
The results ofthis study demonstrate that agents that block the binding of env
gp120 to CD4 inhibit the infection ofboth fresh and precultured (mature) human
peripheralblood M/M. In addition, theydemonstrate that infectionofHIVin M/M
can be enhanced by very low concentrations of anti-HIV antibodies, but that even
under suchconditions, infectionis still blocked by inhibitors ofgp120-CD4binding.
Overall, these results suggest that even under conditions of "enhancement," CD4
binding is an essential component of infection of M/M by HIV.
The abilityoflow concentrations ofantiviral antibodiesto enhance viral infection
invitroisawelldescribedphenomenonforanumberofviruses (especially flaviviruses),
andmay incertain cases beclinicallyimportant (11-13, 29-32). Dengue, forexample,
may be more severe in individuals with low levels of antidengue antibodies than
in seronegative individuals (33, 34). There isevidence that forflaviviruses twomech-
anisms may contribute to this phenomenon. First, antibodies may serve to attach
the virus to either Fc receptors or (indirectly) to complement receptors; the viruses
then enter by receptor-mediated endocytosis (35, 36). Second, the antibodies may
increase the specific infectivity ofbound virus; flaviviruses enter the cytoplasm by
an acid-dependent uncoating process and antibodies appear to make this process
more efficient by altering the pH of virus-containing endosomes (37-39). In con-
trast to the flaviviruses, HIV can enter cells both via acid-dependent and acid-
independent pathways (40), and the latter mechanism may not apply. Also, while
a cellular receptor for flaviviruses has not been clearly identified (in the absence of
antibodies), CD4 isadefined receptor for HIV. Indeed, in the present experiments,
CD4 appears to act as an essential receptor for HIV even in the presence of en-
hancing antibodies. It is possible that anti-HIV antibodies anchor HIV to the cell
surface (via bindingofthe antibody to the Fc receptor), and thus increase the likeli-
hood that thevirus will come into contact withCD4. It isconceivablethat this mech-PERNO ET AL.
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anism might exert a greater effect in cells (such as M/M) where there is a relatively
low expression ofsurfaceCD4. Alternatively, it is possible that anti-HIV antibodies
may enhance viral fusion or some other step that follows binding to CD4. Finally,
binding ofantibody-virus complexes might increase expression of surface CD4 on
target cells. Whatever the mechanism(s), the availableevidence suggests that under
the conditions studied, antibody-mediated enhancement ofM/M still requires viral
binding via CD4 as an essential step.
One must consider whetherthe present results mighthave been caused by toxicity
of sCD4 or OKT4A. This is unlikely to be the case, however, as late addition of
these agents had no effect on HIV production, and there was no other evidence of
toxicity. Thelack ofsuppression ofHIV replication from lateaddition ofsCD4 also
argues against the possibility that this agent might have an effect on virus budding
orotherlate stages in replication in M/M, as has been proposed in othercellsystems
(41). However, as noted above, it is still possible that upon binding to HIV, sCD4
might interfere with cell fusion or viral entry (as opposed to viral binding). Such
a mechanism, however, couldnot account forthe suppression observed with OKT4A,
and taken in toto, the results suggest that CD4 bindingis an essential step for HIV
infection of M/M in the presence of enhancing antibodies.
It should be noted that the results presented here are somewhat in contrast to
these ofHomsyet al. (7), who reported that antibody-induced enhancement ofHIV
infection was not always blocked by inhibitors of gpl20-CD4 binding. Variations
in the M/M populations, the source or strain ofHIV, or anti-HIV antibodies might
account for the differing results, and these issues will have to be explored further.
Also, the experiments reported heredonot involvecoculture ofM/M with indicator
cells that might simply be infected by HIV absorbed onto the surface of M/M (by
antibodies) and thusnot appear to be inhibited byanti-CD4 antibodies orby sCD4.
Additionally, certain M/M preparations mayrelease proteases that maydestroy pro-
teins that inhibit gp120-CD4 binding.
Ithasbeen proposed that antibody-induced enhancementofHIV infection might
have clinical implications in disease pathogenesis, thedevelopmentofa vaccine against
HIV, orcertain therapeutic modalities. However, we could elicit enhancement only
under very stringent conditions (low multiplicity ofinfection and very low concen-
trations ofantibodies), and even then, the effect seen was only moderate. It would
thus appear that clinicallysignificanteffectswould beobserved onlyunder verylimited
conditions, if at all. During a narrow window oftime early in the course ofHIV
infection, for example, enhancing antibodies might cause a burst of HIV infection
(28). Subsequently, however, antibody titers would be higher than those associated
with enhancement. In regard totherapeutic modalities, enhancementhas been pro-
posed to be a theoretical concern in the administration ofhyperimmune anti-HIV
gamma globulin. However, the titers attained in patients with HIVAbl would be
at least 10,000-fold higher than those associated with enhancing activity. Lack of
activity against M/M or enhancement may also be a theoretical concern in the use
of CD4-Ig fusion proteins (19). However, such proteins are effective inhibitors of
HIV infection ofM/M (19), and in preliminaryexperiments, we have notbeen able
to detect enhancement with this agent (C. F Perno, S. Broder, and R. Yarchoan,
unpublishedobservation). Additional studies, however, will beneeded to further assess
the potential clinical implication of these phenomena.1054
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Summary
Infection ofmonocyte/macrophages (M/M) by a variety of viruses (includingHIV1)
has been shown to be enhanced in the presence of low concentrations of antiviral
antibodies. This process has been hypothesized as occurring through binding of the
virus-antibody complex to Fc or complement receptors followed by endocytosis. In
the current study, we explored whether such a mechanism might provide a CD4-
independent route of infection by HIVI for any of several populations of M/M.
In the absence of anti-HIV antibodies, replication of HIV-1 in M/M was blocked
by viral binding inhibitors such as soluble CD4 or OKT4AmAb. Furthermore, while
infection of the M/M populations by a low multiplicity of infection of HIV-1 was
found to be somewhat enhanced by the presence ofvery low concentrations of anti-
HIV antibodies, this process was also consistently inhibited by recombinant soluble
CD4 and by OKT4A antibody. These results suggest that under the variety of con-
ditions studied, CD4 binding was an essential step in the infection ofM/M by HIV.
Moreover, they are consistentwith the notion that "enhancing" antibodies may serve
to concentrate HIV onto CD4 receptors or, alternately, may act at other steps in
the process of viral entry and replication.
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